Mesentech is developing innovative drugs that can selectively deliver drugs to the bone in order to rebuild bone lost to disease, trauma, and to reverse osteoporosis.
Mesentech was founded by Dr. Robert Young, who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. Mesentech lead compound is MES1022, a bone-targeted prodrug that has the potential to reverse bone-loss caused by diseases such as Duchenne muscular dystrophy and osteoporosis. Mesentech is also leveraging bi-specific drug conjugate technology to develop new drugs for hematological and gastrointestinal diseases.
Founders
Bob Young
Pharmaceutical Chemist specializing in drugs for bone formation
Michael Underhill
Stem Cell Biologist researching the mechanisms behind molecular and cellular interaction
Fabio Rossi
Cellular & Molecular Biologist in tissue regeneration and mesenchymal stem cells
Pieter Cullis
Nano-particle Biochemist specializing in drug delivery
Our Partners